Provisional 2026 EPHMRA ATC Developments
The following new class structures were voted on by EPHMRA/Intellus in May/June 2025 and agreed in principle.
These structures will now be used in the next part of the development process which is the detailed refinement of the rules.
Please note that these new class structures are provisional at this time.
The 2026 codes, descriptions and Guideline text will be finalised and published by the Committee at the end of 2025. The new structures then come into effect from the beginning of 2026.
Immunosuppressants - Complement Inhibitors New third level class within L4 (Immunosuppressants) for products containing complement inhibitors indicated for multiple conditions. Currently, these products are classified in L4X (Other immunosuppressants).
Immunosuppressants - Calcineurin Inhibitors New third level class within L4 (Immunosuppressants) for products containing calcineurin inhibitors. Currently, these products are classified in L4X (Other immunosuppressants).
Orexin Antagonists - New fourth level class within N5B (Hypnotics/Sedatives) for products containing orexin receptor antagonists. Currently, these products are classified in N5B1 (Non-barbiturates, plain).